FDA clears lecanemab subcutaneous autoinjector for Alzheimer's
The US Food and Drug Administration has approved a supplemental Biologics Licence Application for lecanemab-irmb subcutaneous injection, marketed as LEQEMBI IQLIK, as an initiation dose for early Alzheimer's disease. The approval, announced jointly by Eisai and Biogen on 13 July 2026, allows patients to begin anti-amyloid therapy at home via an autoinjector rather than attending an infusion clinic.
The approved initiation regimen is 500 mg once weekly, delivered as two 250 mg injections each taking approximately 15 seconds to administer. After 18 months of either intravenous or subcutaneous treatment, patients may transition to a 360 mg once-weekly subcutaneous maintenance dose, which the FDA had already cleared in August 2025. Patients and clinicians retain the option to switch between intravenous and subcutaneous routes at any point, providing what Eisai describes as full flexibility across the treatment journey.
Clinical evidence and safety
The subcutaneous initiation approval is supported by sub-studies from the Phase 3 Clarity AD long-term extension, which showed that once-weekly subcutaneous dosing achieves drug exposure equivalent to intravenous administration. The companies reported that biomarker outcomes, including amyloid removal, and the rate of amyloid-related imaging abnormalities with oedema (ARIA-E) were comparable across both routes. Injection-site reactions were observed with subcutaneous dosing, most of which were localised; severe localised reactions and cases leading to dose interruption or discontinuation were recorded.
The broader ARIA safety profile remains the principal clinical consideration for lecanemab. In the Clarity AD core trial, ARIA was observed in 21% of lecanemab-treated patients versus 9% on placebo. Patients who are ApoE ε4 homozygotes, roughly 15% of the Alzheimer's population, face a materially higher ARIA burden and are subject to a boxed warning. An autoinjector acceptability study involving 50 patients and 50 care partners found 94% rated the device easy to use, though the sample was small and conducted under supervised conditions.
Howard Fillit, co-founder and chief science officer emeritus of the Alzheimer's Drug Discovery Foundation, said the approval gives patients and care partners "meaningful choice in how anti-amyloid treatment is delivered" for the first time.
Market context and competitive landscape
The subcutaneous label extension is commercially significant for Eisai and Biogen. Intravenous anti-amyloid therapies have faced real-world uptake barriers: infusion capacity constraints, nursing oversight requirements, and the burden on patients and care partners of regular clinic attendance. A home-use autoinjector addresses each of those friction points and could meaningfully expand the eligible and willing patient population.
Lecanemab competes directly with Eli Lilly's donanemab (Kisunla), which received full FDA approval in mid-2024 and is also positioned for early Alzheimer's disease. Lilly has not yet disclosed a subcutaneous formulation programme for donanemab at an equivalent stage, which gives lecanemab a near-term differentiation point on route of administration. The broader anti-amyloid class, including earlier-approved aducanumab (which was withdrawn from the US market in 2024), has collectively faced scrutiny over cost, ARIA risk, and the modest absolute magnitude of cognitive benefit observed in trials.
Lecanemab is now approved in 53 countries and regions. The US commercial launch of LEQEMBI IQLIK as an initiation dose is planned for late August 2026, with supply distributed through specialty pharmacy channels. Eisai retains final regulatory decision-making authority under its co-commercialisation agreement with Biogen.